Novo Nordisk Sues Eli Lilly Over Misleading Weight-Loss Drug Ads
Legal·3 articles across 3 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up.
The lawsuit follows a cease-and-desist request and argues that the advertising creates confusion among consumers regarding the efficacy and safety of the competing obesity treatments.
Novo NordiskEli LillyOzempicWegovyZepbound
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs.”
thestreet — Ozempic maker takes biggest rival to court over weight-loss drug ads“<figure><div><img”
healthcare dive — Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs